Allergy Med Singulair to Get 'Black Box' Warning Over Psych Side Effects: FDA

WEDNESDAY, March 4, 2020 (HealthDay News) -- Asthma and allergy drug montelukast -- sold as a generic and under the brand name Singulair -- will get a "boxed warning" over potential ties to neuropsychiatric effects, the U.S. Food and Drug Administration announced on Wednesday.

The drug has long carried a warning that it has been linked with an increased risk of "agitation, depression, sleeping problems, and suicidal thoughts and actions," the FDA said in a statement.